Martin Andreansky
Overview
Explore the profile of Martin Andreansky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
206
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Eapen M, Kou J, Andreansky M, Bhatia M, Brochstein J, Chaudhury S, et al.
Am J Hematol
. 2024 Feb;
99(4):785-788.
PMID: 38343182
No abstract available.
2.
Shah N, Bhoopatiraju S, Abraham A, Anderson E, Andreansky M, Bhatia M, et al.
Transplant Cell Ther
. 2021 Dec;
28(3):174.e1-174.e5.
PMID: 34958973
Granulocyte colony-stimulating factor (G-CSF) used after hematopoietic stem cell transplantation (HSCT) can enhance neutrophil recovery in patients rendered neutropenic by the preparative regimen. G-CSF is contraindicated in patients with sickle...
3.
Bhatt S, Bednarski J, Berg J, Trinkaus K, Murray L, Hayashi R, et al.
Biol Blood Marrow Transplant
. 2018 Oct;
25(3):556-561.
PMID: 30321596
Hematopoietic stem cell transplantation (HSCT) is a therapeutic option for many nonmalignant disorders (NMD) and is curative or prevents disease progression. Reduced-intensity conditioning (RIC) in HSCT for NMD may reduce...
4.
Shenoy S, Walters M, Ngwube A, Soni S, Jacobsohn D, Chaudhury S, et al.
Biol Blood Marrow Transplant
. 2018 Jan;
24(6):1216-1222.
PMID: 29374585
Allogeneic hematopoietic stem cell transplantation (HSCT) can cure transfusion-dependent thalassemia (TDT). In a multicenter trial we investigated the efficacy of reduced-intensity conditioning (RIC) before unrelated donor (URD) HSCT in children...
5.
Shenoy S, Eapen M, Panepinto J, Logan B, Wu J, Abraham A, et al.
Blood
. 2016 Sep;
128(21):2561-2567.
PMID: 27625358
Children with sickle cell disease experience organ damage, impaired quality of life, and premature mortality. Allogeneic bone marrow transplant from an HLA-matched sibling can halt disease progression but is limited...
6.
King A, Kamani N, Bunin N, Sahdev I, Brochstein J, Hayashi R, et al.
Am J Hematol
. 2015 Sep;
90(12):1093-8.
PMID: 26348869
Fifty-two children with symptomatic sickle cell disease sickle cell disease (SCD) (N = 43) or transfusion-dependent thalassemia (N = 9) received matched sibling donor marrow (46), marrow and cord product...
7.
Kably I, Ziga E, Andreansky M
Pediatr Blood Cancer
. 2015 Jul;
62(12):2226-8.
PMID: 26179050
Acute gastrointestinal graft-versus-host disease (GVHD) refractory to first-line treatment with systemic corticosteroids results in increased morbidity and potential mortality. We retrospectively assessed the feasibility and efficacy of catheter-directed intra-arterial platelet...
8.
Lund T, Cathey S, Miller W, Eapen M, Andreansky M, Dvorak C, et al.
Biol Blood Marrow Transplant
. 2014 Jul;
20(11):1847-51.
PMID: 25016194
Mucolipidosis type II (MLII), or I-cell disease, is a rare but severe disorder affecting localization of enzymes to the lysosome, generally resulting in death before the 10th birthday. Although hematopoietic...
9.
Colin A, Shafieian M, Andreansky M
Pediatr Pulmonol
. 2010 Feb;
45(4):411.
PMID: 20187104
No abstract available.
10.
Kohoutova Z, Rumlova M, Andreansky M, Sakalian M, Hunter E, Pichova I, et al.
Virology
. 2008 Dec;
384(1):59-68.
PMID: 19062065
Most retroviruses employ a frameshift mechanism during polyprotein synthesis to balance appropriate ratios of structural proteins and enzymes. To investigate the requirements for individual precursors in retrovirus assembly, we modified...